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Abstract:  
Background: The trypanocidal agent, diminazine have been shown to produce 
some toxic effects such as itching, hypotension and gastrointestinal disturbances 
among the migratory domestic animals, especially in camels during the dry season 
in South-western Sudan.                                                                  
Objective: The present study was an attempt to explain some toxic effects of 
diminazine in vitro.  
Methods: A number of qualitative and quantitative experiments have been done to 
elucidate these mechanisms using different concentrations of diminazine.   
Results: Incubation of different concentrations of diminazine with rat lung chops 
and their intraperitoneal administration, produced incubates that potently stimulated 
the isolated guinea-pig ileum. The obtained contractions were dosedependent and 
effectively blocked by the anti-histamine, diphenhydramine. The yielded incubated 
mixtures when developed on paper chromatography with authentic samples showed 
two spots with Rf values and colours similar to those of heparin and histamine when 
sprayed with ninhydrin or exposed to iodine vapour. The extent to which diminazine 
released histamine was determined by measuring the concentrations of the released 
histamine using the three-point assay. The addition of EDTA, diltiazem and 
dinitrophenol separately to the incubated mixtures indicated that the release of 
histamine and the accompanied heparin was calcium-and energy-dependent, most 
probably by exocytosis and damaging the lung and peritoneal mast cells.   
When tested on isolated rabbit jejunum, diminazine was found to potentiate the 
effect of histamine with pA1/2 value of 5.4 ± 0.13 compared to 5.6 ± 0.15 for 
aminoguanidine, the standard diamine oxidase inhibitors.  
Conclusion: Diminazine was found to have a potent histamine releasing capacity. 
These findings indicated that the severe toxic effects produced by diminazine might 
be due to its ability to release histamine and/or potentiating its effects.   
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Introduction:   
Trypanosomiasis is a disease that affects both human and animal in all tropical 
areas. The disease has a major economic importance in Africa; especially in tsetse 
endemic areas (1). In Sudan, trypanosomiasis was first described in 1904 in donkeys 
and camels in Bahr Elgazal and in cattle in Malut in the Upper Nile and in some 
other parts of the country. During the dry season of the year 1983, there was an 
outbreak of trypanosomiasis among the migratory domestic animals, especially in 
camels (2). The use of antitrypanosomal drugs for cure and prophylaxis of 
trypanosomal infection is one of the several techniques used in controlling 
trypanosomal infection in man and animals. Treatment and prophylaxis of 
trypanosomiasis in cattle, sheep and goats is dependent upon the most important 
three compounds; diminazine aceturate, homidium and isometamidium (3).  The 
treatment of livestock with standard therapeutic doses of diminazine (3.3-7 mg/kg) 
sometimes results in signs of toxicity (4). In camels, however, a single dose of 7 
mg/kg can be highly toxic. Diminazine is also relatively toxic in dogs (5). 
Experimentally, intramuscular administration diminazine in doses exceeding 10 
mg/kg, once or repeatedly, results in severe signs of disturbances in the 
gastrointestinal tract, musculoskeletal, respiratory and nervous systems; hypotension 
and itching are also observed in both camels and dogs (6). In laboratory rodents, 
hypotension is commonly observed (7). At necropsy, gross and histopathological 
lesions have been described in the liver, urinary bladder, lungs, heart and brain of 
dogs and camels.   
The current study was carried out to explain the mechanisms of some toxic effects 
of diminazine in vitro.  
Materials and Methods:  
Qualitative Bioassay  
Different concentrations (10, 20, 40, 80, 160, 320 µg/ml) of the trypanocidal agent, 
diminazine (Berenil, Hoechst Co. Ltd) were used and incubated separately with rat 
lung chops. The obtained incubates were separately assayed using guinea-pig ileum 
preparation and oscillograph (Harvard Apparatus Limited). The resultant 
contractions were effectively blocked by the antihistamine diphenhydramine 
maleate (100 ng, Sigma Chemical Co.) (8). Histamine (Sigma Chemical Co) and 
heparin (Rotexmedick, GMPH, Germany) were used as authentic samples and co-
chromatographed with incubates on paper (Whatman No. 1); n-butanol, acetic acid 
and water (BAW 4:1:5) were used as solvent system. Quantitative Bioassay  
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Also another concentrations of diminazine (10, 20, 40, 80, 160, 320 µg/ml) were 
incubated separately with rat lung chops and the obtained mixtures were assayed 
against standard known concentrations of histamine (5, 10, 20, 40 ng/ml) using the 
guinea-pig ileum preparation and oscillograph. The same concentrations of 
diminazine were administered intraperitoneally to rats and the obtained incubated 
mixtures were assayed by the same previously mentioned method. The chelating 
agent EDTA (5 ng/ml), diltiazem (20 mg/ml) and dinitrophenol (5 ng/ml) were 
added separately to the incubated mixtures to elucidate the mechanism by which 
diminazine may release histamine.  
Aminoguanidine, in different concentrations (0.1, 0.2, 0.4, and 0.8 µg/ml) and 
diminazine in concentrations of (1, 2, 4 and 8 µg/ml) were studied separately in 
isolated rabbit jejunum to determine their effects on the enzyme, diamine oxidase, 
by measuring their pA1/2 values. (8)     
Statistical Analysis  
Data were expressed as means ± standard error of means (SEM). Each value is the 
mean of three experiments.  
Results and Discussion:  
The biological assays of the different incubated mixtures of diminazine in high 
concentrations (80, 160, and 320 µg/ml), using guinea-pig ileum preparation, 
resulted in a concentration-dependent contraction of guinea-pig ileum. The various 
responses produced by the different incubates of diminazine on the guinea-pig ileum 
were effectively blocked by the anti-histamine, diphenhydramine (100 ng/ml). 
Moreover, paper chromatographic analysis predominantly showed the presence of 
two brown spots after exposure to iodine vapour and ninhydrin spray. The two 
brown spots have the same Rf values as authentic histamine and heparin, which 
indicated that there may be a release of histamine by diminazine accompanied by 
release of heparin from the rat lung mast cells. Diminazine may facilitate the 
process of exocytosis of the content of the mast cell granules, which may result in 
degranulation of the mast cells and the release of histamine and heparin (9). This 
may explain the mechanism by which diminazine induced this release. The addition 
of low concentrations of diminazine (10 and 20 µg/ml) to the rat lung chops may 
result in slight release of histamine; this was evident as very weak contractions were 
produced when the incubated mixtures were assayed using guinea-pig ileum 
preparation and oscillograph. These contractions were also blocked by 
diphenhydramine (100 ng/ml).    
As shown in Table 1, the incubated mixtures of higher concentrations of diminazine 
(40, 80, 160 and 320 µg/ml) resulted in different contractions when assayed 
separately against histamine using guinea-pig preparation and oscillograph. The rate 
of histamine release increased as the concentrations of diminazine increased. These 
responses were also blocked by diphenhydramine (100 ng/ml).   
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Table 1: Mean Histamine Release from Rat Lung Mast Cells by Different 




Histamine Released by Diminazine  
Concentrations (ng/gm) wet weight of 
lung tissues)  
40  27±0.16  
80  48±0.14  
160  65±0.135  
320  115±0.11  
  
The release of histamine from rat peritoneal mast cells by diminazine occurred in a 
concentration-dependent manner when different incubates of diminazine were 
assayed separately against histamine using guinea-pig ileum preparation and 
oscillograph. The responses produced by diminazine were inhibited by 
diphenhydramine (100 ng/ml), (Table 2). It was also shown that diminazine caused 
more release of histamine from rat lung chops and peritoneal mast cells. This 
release of histamine may explain some of the toxic effects of diminazine such as 
itching and hypotension and gastrointestinal disturbances.  
  
Table 2: Mean Histamine Release from Rat Lung Peritoneal Mast Cells by     




Histamine Released by Diminazine 
Concentrations (ng/gm.wt)  
20   13±0.23 
40  23±0.19  
80  42±0.15  
160  73±0.13  
  
The chelating agent ethylene diamine tetra acetic (EDTA) inhibited the release of 
histamine from the rat lung mast cells when the different lower concentrations (10, 
20, 40, and 80 µg/ml) of diminazine were incubated separately with rat lung tissue. 
No responses were produced when the different incubated mixtures of diminazine 
were assayed using guinea-pig ileum as the presence of EDTA inhibits the 
exocytotic release of histamine since calcium ions are necessary for exocytosis (9). 
In the current study, the release of histamine is a calcium dependent process.  
The addition of the calcium channel blocker, diltiazem, to the chopped tissues in the 
presence of diminazine seems to retard the release of histamine, where no 
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contractions were produced when different incubated mixtures were assayed 
separately using guinea-pig ileum preparation. Thus the presence of diltiazem in the 
incubate may have some direct effect on the tissue or may affect the calcium 
channels or calcium content within the tissue, and that confirmed the previous 
results obtained with EDTA.  
Furthermore, the addition of dinitrophenol (inhibitor of ATP synthesis) to the 
different incubates of diminazine showed inhibition of histamine release from rat 
lung mast cells, as no contractions or responses were obtained when different 
incubates of diminazine were assayed separately using the guinea-pg ileum 
preparation. This indicated that the release of histamine is energy-dependent 
process.  
It was also noticed that the addition of diminazine at the concentrations (1, 2, 4, and 
8 µg/ml) potentiated the responses of half-submaximal dose o histamine. This 
indicated that diminazine also have inhibitory effects on the enzyme diamine 
oxidase.  
It was early reported that diminazine at doses similar to those releasing histamine 
may also seem to inhibit acetylcholinesterases, which may result in increasing 
acetylcholine concentrations that may explain some of the toxic effects produced by 
diminazine (10).   
Toxicity studied have been associated to either the release of or an interaction with 
autacoids such as serotonin and histamine and cholinergic agents by the 
trypanocidal drugs within the host tissue. (11-14)  
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